6,460 results match your criteria: "Oncology Institute.[Affiliation]"
Cancers (Basel)
September 2024
Cyclotron Centre Bronowice, Institute of Nuclear Physics Polish Academy of Sciences, PL31342 Kraków, Poland.
Applying a proton beam in radiotherapy enables precise irradiation of the tumor volume, but only for continuous assessment of changes in patient anatomy. Proton beam range uncertainties in the treatment process may originate not only from physical beam properties but also from patient-specific factors such as tumor shrinkage, edema formation and sinus filling, which are not incorporated in tumor volume safety margins. In this paper, we evaluated variations in dose distribution in proton therapy resulting from the differences observed in the control tomographic images and the dosimetric influence of applied adaptive treatment.
View Article and Find Full Text PDFBMC Cancer
September 2024
Department of Respiratory and Critical Care Medicine, Enze Hospital, Taizhou Enze Medical Center (Group), Taizhou, Zhejiang Province, 318050, China.
Indian J Ophthalmol
October 2024
Department of Medical Oncology (Institute Rotary Cancer Hospital), All India Institute of Medical Sciences, New Delhi, India.
Purpose: The coronavirus disease 2019 (COVID-19) pandemic led to overall interrupted medical care, resulting in disease progression and morbidity. The study aimed to evaluate clinicopathological presentations and severity of eyelid malignancy during the COVID era, comparing the results with patients presented during pre-COVID era and evaluating the reasons for delayed presentation in patients with advanced eyelid malignancy in the COVID-era.
Methods: This was a comparative, ambispective observational study.
Vet Sci
September 2024
Animal and Veterinary Research Centre (CECAV), University of Trás-os-Montes and Alto Douro (UTAD), 5000-801 Vila Real, Portugal.
Cancer is a complex pathological condition associated with substantial rates of mortality and morbidity in both humans and animals. Mammary gland tumors in intact female dogs are the most prevalent neoplasms. Surgical intervention remains the primary treatment choice.
View Article and Find Full Text PDFCurr Issues Mol Biol
September 2024
Department of Surgery, Istanbul Faculty of Medicine, Istanbul University, 34093 Istanbul, Turkey.
Despite the use of screening programs, gastric cancer (GC) diagnosis may only be possible at an advanced stage. In this study, we examined the serum levels of C-C chemokine receptor type 5 (CCR5), C-C motif chemokine ligand 5 (CCL5), platelet-derived growth factor (PDGF), and EphrinA7 (EphA7) in patients with gastric carcinoma and healthy controls to investigate the significance and usability of these potential biomarkers in the early diagnosis of GC. The study enrolled 69 GC patients and 40 healthy individuals.
View Article and Find Full Text PDFJ Comp Eff Res
November 2024
ICBAS School of Medicine & Biomedical Sciences, University of Porto (UP), Porto, Portugal.
Lung cancer is the most common cause of cancer death in Portugal. The Dutch-Belgian lung cancer screening (LCS) study (NELSON), the biggest European LCS study, showed a lung cancer mortality reduction in a high-risk population when being screened. In this study, the cost-effectiveness of LCS, based on the NELSON study protocol and outcomes, was evaluated compared with no screening in Portugal.
View Article and Find Full Text PDFEur Urol Oncol
September 2024
The Royal Free London NHS Foundation Trust, London, UK; UCL Division of Surgery and Interventional Science, University College London, London, UK; Department of Urology, The Netherlands Cancer Institute, Antoni van Leeuwenhoek Hospital, Amsterdam, The Netherlands.
Hematol Oncol
November 2024
Oncology Institute of Southern Switzerland, Ente Ospedaliero Cantonale, Bellinzona, Switzerland.
Eur J Med Genet
December 2024
Oncology Institute, Division of Pediatric Hematology-Oncology, Istanbul University, Istanbul, Türkiye. Electronic address:
Hodgkin's lymphoma (HL) is the most common cancer in adolescents and young adults. A family history of HL increases the risk of developing HL in other family members. Identification of genetic predisposition variants in HL is important for understanding disease aetiology, prognosis, and response to treatment.
View Article and Find Full Text PDFEndoscopy
November 2024
Francisco Gentil Portuguese Institute for Oncology of Coimbra, Gastroenterology Department, Portuguese Oncology Institute of Coimbra (IPO Coimbra), Coimbra, Portugal.
Background: Mucosal visualization during upper gastrointestinal (UGI) endoscopy can be impaired by the presence of foam, bubbles, and mucus. Some UGI endoscopy visibility scales have been proposed but have not undergone multicenter validation. This study aimed to develop and validate the Gastroscopy RAte of Cleanliness Evaluation (GRACE) scale.
View Article and Find Full Text PDFContemp Nurse
September 2024
Ospedale Regionale Bellinzona e Valli, Ente Ospedaliero Cantonale, via A. Gallino 12, 6500, Bellinzona, Switzerland.
: Bladder ultrasound (BUS) provides an accurate measurement of post-void residual (PVR) volume and bladder assessment. Access to BUS is dependent on practitioner availability with delays resulting in poor symptom management, delayed discharge and dissatisfaction. Developing nursing practice to perform BUS can address these patient's needs.
View Article and Find Full Text PDFNEJM Evid
October 2024
Medical Oncology 2, Veneto Institute of Oncology IOV-IRCCS, Padova, Italy.
Background: The impact of the order of treatment with checkpoint inhibitors or BRAF/MEK inhibitors on the development of brain metastases in patients with metastatic unresectable V600-mutant melanoma is unknown. The SECOMBIT trial examined the impact of the order of receipt of these treatments in such patients.
Methods: In this three-arm trial, we reviewed patients without brain metastases who received the BRAF/MEK inhibitors encorafenib and binimetinib until they had progressive disease followed by the immune checkpoint inhibitors ipilimumab and nivolumab (arm A); or treatment with ipilimumab and nivolumab until they had progressive disease followed by encorafenib and binimetinib (arm B); or treatment with encorafenib and binimetinib for 8 weeks followed by ipilimumab and nivolumab until they had progressive disease followed by retreatment with encorafenib arm binimetinib (arm C).
J Surg Oncol
September 2024
Department of General Surgery C and Surgical Oncology, Sheba Medical Center, Ramat Gan, Israel, Tel-Aviv University, Tel-Aviv, Israel.
Front Endocrinol (Lausanne)
September 2024
Unit for Multidisciplinary Research in Biomedicine (UMIB), School of Medicine and Biomedical Sciences (ICBAS), University of Porto, Porto, Portugal.
Eur Urol Open Sci
October 2024
Department of Medical Oncology and Haematology, Cantonal Hospital St. Gallen, St. Gallen, Switzerland.
Semin Nucl Med
November 2024
Service de médecine nucléaire, Hôpital Tenon, Assistance Publique-Hôpitaux de Paris, Paris, France; Institut National des Sciences et Techniques Nucléaires (INSTN), Saclay, France.
Cancer Cell
October 2024
Institute of Oncology Research (IOR), 6500 Bellinzona, Switzerland; Università della Svizzera Italiana, Faculty of Biomedical Sciences, CH6900 Lugano, Switzerland; Medical Oncology Unit, Oncology Institute of Southern Switzerland, Ente Ospedaliero Cantonale, CH6500 Bellinzona, Switzerland; Veneto Institute of Molecular Medicine, 35129 Padova, Italy; Department of Medicine, University of Padova, 35121 Padova, Italy; Department of Health Sciences and Technology (D-HEST) ETH Zurich, 8092 Zurich, Switzerland. Electronic address:
J Med Life
June 2024
Department of Obstetrics and Gynecology, Carol Davila University of Medicine and Pharmacy, Bucharest, Romania.
Endometrial cancer is a complex disease influenced by both somatic and germline mutations. While individual mutations in genes such as , and members of the DNA mismatch repair (MMR) system have been extensively studied, comprehensive analyses comparing somatic and germline mutations within the same cohort are limited. This study compares these mutations using whole exome sequencing (WES) data from tumor and blood samples in patients with endometrial cancer.
View Article and Find Full Text PDFESMO Open
October 2024
Medical Oncology Department, U.O.C. Clinica di Oncologia Medica, IRCCS Ospedale Policlinico San Martino, Genoa; Department of Internal Medicine and Medical Specialties (DIMI), School of Medicine, University of Genova, Genoa.
Oral Dis
September 2024
BoneLab - Laboratory for Bone Metabolism and Regeneration, Faculty of Dental Medicine, University of Porto, Porto, Portugal.
Objectives: This case study evaluated the efficacy of mid-infrared spectroscopy on the identification of oral squamous cell carcinoma, following the assessment of unstimulated whole saliva.
Study Design And Methods: The trial follows a matched case-control design. Saliva samples were characterized through mid-infrared spectroscopy, and chemometric tools were applied to distinguish between case and control participants, further identifying the spectral regions that played a pivotal role in the successful identification of oral squamous cell carcinoma.
Front Oncol
August 2024
Division of Oncology/Hematology, Cantonal Hospital Graubünden, Chur, Switzerland.
Immunotherapy with checkpoint inhibitors including atezolizumab, pembrolizumab and nivolumab has become an essential pillar in the management of muscle invasive and metastatic urothelial carcinoma. The field has evolved quickly in the past few years and several early beliefs have recently been upended. One such belief relates to the predictive value of PD-L1 expression based on immunohistochemistry.
View Article and Find Full Text PDFRadiother Oncol
December 2024
South Australian Immunogenomics Cancer Institute, University of Adelaide, Adelaide, Australia.
Cancer Treat Rev
November 2024
Oncology Institute of Southern Switzerland, EOC-IOSI, Via A. Gallino 12, CH - 6500 Bellinzona, Switzerland. Electronic address:
The aim of this review is to provide an overview of the status of patient/public involvement (PPI) in oncology research, including definitions, regulatory aspects, ongoing clinical activities in different countries, achievements and difficulties. The 10-year activities of the Swiss Group for Clinical Cancer Research (SAKK) Patient Advisory Board are described, illustrating challenges faced and solutions in daily practice. Even though clinical data are still limited, it appears PPI has great potential for development in oncology.
View Article and Find Full Text PDFNeoplasma
August 2024
Department of Radiation Oncology, Faculty of Medicine, Masaryk University, Brno, Czech Republic.
The optimal treatment of oropharyngeal cancer (OPC) associated with human papillomavirus (HPV) is currently a subject of clinical research. This questionnaire study investigated current trends in the treatment of HPV-associated (HPV+) OPC in Slovakia with the incorporation of deintensification of oncological treatment into routine clinical practice outside of clinical trials. The Slovak Cooperative Head and Neck Cancer Group (SCHNCG) developed a questionnaire aimed at identifying trends in the oncological treatment of HPV+ OPC intended for all radiation oncology (RO) facilities in Slovakia.
View Article and Find Full Text PDF